Condition
Atypical Neurofibroma
Total Trials
4
Recruiting
1
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 1 (1)
Trial Status
Active Not Recruiting3
Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT06515860Active Not Recruiting
Neurofibromatosis Type 1 Tumor Early Detection Study
NCT06735820Phase 1Recruiting
Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST
NCT05677594Active Not Recruiting
Multi-parametric Biomarker Development to Predict Malignant Conversion in Patients With Neurofibromatosis Type 1
NCT03820778Not ApplicableActive Not Recruiting
Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1
Showing all 4 trials